c-MET (hepatocyte growth factor receptor) is a receptor tyrosine kinase, which activates MAPK, PI3K/AKT, SRC, and STAT pathways to promote cell proliferation, invasion and angiogenesis. Simple variants in MET are seen in about 1.5% of all tumors, including 4% of skin tumors, 3% of kidney tumors, and 2% of lung and colorectal tumors. MET alterations are diagnostic of a certain kidney tumor (papillary). MET activating mutations predict response to MET inhibitors.